MedPath

The influence of oral contraceptives on lamotrigine clearance in patients on lamotrigine in combination with valproic acid, carbamazepine or oxcarbazepine as compared to patients on lamotrigine only.

Completed
Conditions
epilepsy
10029305
Registration Number
NL-OMON32536
Lead Sponsor
Stichting Epilepsie Instellingen Nederland
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
28
Inclusion Criteria

women in the age of 18-40 years that use OC in a stable dose as well as a stable dose of 1)LTG and VPA, 2)LTG and CBZ, 3)LTG and OCB.

Exclusion Criteria

Use of steroid hormones (other than OC) as well as pregnancy or the intention to conceive, current breastfeeding or having delivered in the nine months prior to the study. Patients with abnormal liver and/or renal function or with known gynaecological or psychiatric co morbidity will be excluded.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>LTG serum levels as well as serum levels of VPA, or CBZ or OCB during the<br /><br>cycles will be primary study parameters.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>seizures and side effects will be secundary parameters.</p><br>
© Copyright 2025. All Rights Reserved by MedPath